Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36 clinical trials
Device-Less Technique in Islet Transplantation

Islet transplantation is an effective modality for treating type 1 diabetes. Despite marked progress in clinical islet transplantation with the achievement and maintenance of insulin independence in over half of recipients up to 5 years, transplant approaches are limited to those that struggle to control their diabetes. Furthermore, this approach …

plasma glucose
insulin
diabetes
hypoglycemia
diabetic ketoacidosis
  • 0 views
  • 27 May, 2022
  • 1 location
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

This is a Phase II prospective trial to assess the rates of donor engraftment using reduced intensity conditioning (RIC) hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) for patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), and inherited bone marrow failure syndromes (IBMFS).

wiskott-aldrich syndrome
thrombocytopenia absent radii
immunodeficiency
ipex
cyclophosphamide
  • 3 views
  • 24 Feb, 2022
  • 1 location
Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

All patients undergoing allogeneic or autologous HSCT at the participating centres will be observed. Once a diagnosis of CNS disorder is made, additional data will be reported for these patients. We will identify clinical and diagnostic characteristics such as cerebrospinal fluid (CSF) and neuroimaging patterns, risk factors, response to treatment …

cell transplantation
antifungal
colony stimulating factor
  • 0 views
  • 20 Jun, 2022
  • 17 locations
Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients

In this study the investigators will prospectively investigate whether the addition of a 3-months long preconditioning with azathioprine to the alemtuzumab/TBI non-myeloablative conditioning

hydroxyurea
sirolimus
thalassemia
cell transplantation
alemtuzumab
  • 0 views
  • 15 Mar, 2022
  • 1 location
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC (PRO-RIC)

This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing

  • 0 views
  • 26 Mar, 2022
  • 1 location
Observatory of Prolymphocytic Leukemia T

response to conventional chemotherapy. Treatment with the anti-CD52 monoclonal antibody: alemtuzumab has considerably improved the results, but the responses to treatment are transient; therefore

monoclonal antibodies
AKT
  • 0 views
  • 24 Jan, 2021
  • 1 location